Baxter International Inc. (NYSE:BAX), renowned globally for its excellence in injectables, anesthesia, and drug compounding, has unveiled a significant expansion of its Pharmaceuticals portfolio with the introduction of five new injectable products in the United States. Alok Sonig, Executive Vice…
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has revealed that it will present 13 abstracts from its extensive neuroscience portfolio and pipeline at the 76th Annual American Academy of Neurology Meeting (AAN), scheduled for April 13-18, 2024, in Denver. Among these presentations,…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in…
The latest Global Hepatitis Report by the World Health Organization (WHO) for 2024 reveals a concerning rise in deaths attributed to viral hepatitis. This disease now stands as the second leading infectious cause of death worldwide, claiming as many as…
Teva Pharmaceuticals Unveils Promising PK Modeling Data and Clinical Insights at SIRS 2024 At the Schizophrenia International Research Society (SIRS) 2024 Congress, Teva Pharmaceuticals, a leading U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has revealed significant…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has unveiled promising outcomes from the KARDIA-2 Phase 2 investigation, evaluating the effectiveness and safety of zilebesiran when combined with one of three standard antihypertensive medications: a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine), or…
BioNTech SE (Nasdaq: BNTX) has released promising findings from a Phase 1 trial involving the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran (also known as BNT122, RO7198457) for patients with resected pancreatic ductal adenocarcinoma (PDAC). The study, conducted over…
Merck, known as MSD outside of the United States and Canada, has announced the commencement of a Phase 3 clinical trial to evaluate MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the initial treatment of…
The recent occurrences of avian influenza outbreaks, observed last year, underscore the sobering reality of zoonotic influenza. These events emphasize that individuals of all ages are susceptible, regardless of comorbidities, and that various exposures can lead to avian influenza infection.…
Last year witnessed several outbreaks that underscore the reality of zoonotic influenza, revealing vulnerabilities across all age groups and highlighting the risks for individuals both with and without comorbidities. These outbreaks also emphasized the various exposures that can lead to…
Novartis Unveils Positive CHMP Endorsement for Fabhalta® in Treating Paroxysmal Nocturnal Hemoglobinuria (PNH) Novartis has disclosed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a favorable opinion, recommending the authorization…
WuXi Biologics (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has proudly announced its recognition for exemplary corporate transparency and commitment to water security by the esteemed environmental non-profit CDP, securing its position on the prestigious annual…
